Letter to the editor regarding “Value of 3D-presumed circular area ratio in MRI assessment of benign prostatic hyperplasia” - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correspondence on the Study of 3D-Presumed Circular Area Ratio in MRI Evaluation of Benign Prostatic Hyperplasia

  • By

  • Ajay Guru

  • September 26, 2026

Share

Objective:

To discuss the findings of the study on 3D-presumed circular area ratio (3D-PCAR) in MRI assessment of benign prostatic hyperplasia (BPH).

Approach:
  • Study Evaluation: The correspondence evaluates the study by Yang J et al. regarding the effectiveness of 3D-PCAR in assessing BPH severity.
  • Suggestions for Improvement: The authors provide suggestions for enhancing the study's methodology and clinical applicability.
Key Findings:
  • 3D-PCAR showed stronger correlations with IPSS in coronal and sagittal planes compared to axial measurements.
  • 3D-PCAR provides incremental value beyond conventional volumetric parameters.
Interpretation:

Further examination of technical differences, field strength effects, and validation against urodynamic parameters is suggested.

Limitations:
  • Exclusion of patients with indwelling catheters may affect IPP measurements.
  • A specific PCAR threshold for clinically significant BPH is not provided.
Conclusion:

Addressing the suggested points may enhance the clinical impact of the study.

Sources:

Original Source(s)

Letter to the editor regarding “Value of 3D-presumed circular area ratio in MRI assessment of benign prostatic hyperplasia”

  • by Ajay Guru

  • September 26, 2026

Related Content

A U-Net Transformer for magnetic resonance elastography

Next-Generation Vascular Surgery: Bridging Expertise and Innovation

Vascular surgery continues to evolve as new endovascular technologies, hybrid procedures and emerging applications of artificial intelligence expand how physicians can approach complex vascular disease.

  • by

  • September 18, 2026

  • 5 min
FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.